Medtronic’s VitalFlow™ ECMO System represents a significant leap in extracorporeal life support technology, bringing a smarter, more intuitive solution to the forefront of critical care. Developed through Medtronic’s acquisition of MC3 Cardiopulmonary, the system builds on decades of ECMO innovation and is engineered for both adult and pediatric patients. Designed with user-friendly functionality and a scalable, upgradeable architecture, VitalFlow simplifies complex ICU procedures and enables consistent, high-performance operation across varying levels of clinical expertise. Its integrated design reflects a deep understanding of the challenges facing today’s intensive care units, where time, precision, and adaptability are essential.

The CE Mark approval in Europe marks a major milestone in Medtronic’s strategy to transform ECMO accessibility and usability. With the VitalFlow system, clinicians gain access to a streamlined platform that includes essential components such as oxygenators and catheters—built for seamless performance and reliability. The system’s intuitive interface empowers multidisciplinary ICU teams to manage ECMO therapy confidently, reducing reliance on highly specialized staff and minimizing training burdens. This is especially critical in high-acuity settings and during emergencies where rapid setup and decision-making are vital.

As Europe faces rising demand for advanced cardiopulmonary support solutions, VitalFlow positions Medtronic as a leader in the evolution of life-sustaining care. The system not only improves operational efficiency but also supports long-term patient outcomes by enabling more consistent and timely interventions. Its launch strengthens Medtronic’s already comprehensive cardiovascular portfolio, reinforcing its commitment to delivering integrated solutions that restore health and extend life. VitalFlow’s entry into the European market signals a new era in ECMO delivery—making critical care more accessible, adaptable, and focused on what matters most: saving lives.